Zwolle, Netherlands, November 2nd ( GLOBE NEWSWIRE ) – P95 Julius Clinical has today been renamed AKEURA, becoming a global professional contract research organization with dual expertise in both clinical and real-world settings ( CRO ). The launch of the AKEURA brand is a result of the successful integration following the merger between P95 and Julius Clinical in 2025.
AKEURA provides support to customers covering all stages of clinical development as well as real-world evidence ( RWE ), with a focus on neuroscience, infectious diseases and vaccines, as well as cardiometabolic diseases. As regulatory authorities increasingly turn to real-world data to inform decisions throughout the product lifecycle, the need to integrate clinical development with real-world expertise from the very beginning is more urgent than ever. This also makes the launch of this new brand by AKEURA particularly timely.
AKEURA CEO Bassem Saleh stated: "Every research project boils down to thousands of decisions, and to make these decisions well, it is essential to provide the people making them with the necessary information and technology. Today, this belief has a name: AKEURA. With over 25 years of experience, we are bringing together the specialized capabilities needed to make better decisions at every stage of clinical research. As a result, we deliver more intelligent and efficient research for our clients, a more considerate experience for research centers and participants, and clearer answers for patients waiting for new therapies."
AKEURA employs over 500 researchers, clinicians, and scientists, with operations spanning five continents. They have completed more than 1,000 studies, including over 600 clinical trials and 400 real-world evidence projects, covering over 75 countries. The company's experience encompasses over 700,000 participants and more than 5,000 research centers, involving a range of studies from key therapeutic research to large-scale vaccine trials. Their business also extends to populations that are difficult to reach globally, such as in Africa; the company's team has been working in these regions for over 25 years. By leveraging a network of specialized research centers and close partnerships with local institutions, they bring their research closer to the people they serve.
Behind these numbers lies a model that puts people at its core. AKEURA will match corresponding experts according to the needs of each study, and the senior experts who develop the plans will also continue to be deeply involved throughout the project's progress. Key opinion leaders are also part of this model; practicing doctors and leading researchers participate in the work within AKEURA's own team and advisory network, helping to shape the research design from the very earliest stages of decision-making.
AKEURA Executive Chairman Daniel Spasic stated: "The reason Ampersand Capital Partners invested in Julius Clinical and P95 is that both companies have a long-standing reputation in their respective fields and have earned the trust of their customers. By completing the integration and launching the brand as a single entity under AKEURA, we believe that the customers of AKEURA and the communities they serve will be able to make more seamless use of the integrated professional capabilities and services. AKEURA will provide experts on both sides of evidence-based issues for customers within the framework of a single company. We are grateful to our employees and partners who have supported us throughout this process and look forward to continuing to support more research in neuroscience, infectious diseases and vaccines, as well as cardiometabolic diseases, during the next phase of growth under AKEURA."
AKEURA This week, a new brand will be showcased at CNS Summit (November 1st to 4th) held in Boston, and it will make its debut next week at ISPOR Europe (November 8th to 11th) in Vienna, where its experts will meet with clients.
About AKEURA
AKEURA is a professional contract research organization ( CRO ) that focuses on clinical and real-world settings, possessing expertise in both early-stage to late-stage clinical development as well as real-world evidence ( RWE ). With over 25 years of experience and a team of more than 500 researchers, clinicians, and scientists across five continents, AKEURA helps clients advance drugs throughout their entire lifecycle, with a focus on three therapeutic areas: neuroscience, infectious diseases and vaccines, and cardiometabolic diseases. In each area, the company provides the necessary research for every promising drug, leveraging its experience, coverage, and hands-on professional capabilities. AKEURA originated from P95 Julius Clinical and is headquartered in Zeist, Netherlands, with support from Ampersand Capital Partners. For more information, please visit akeura.com.
About Ampersand Capital Partners
Ampersand Capital Partners was founded in 1988 and is a mid-sized private equity firm that manages assets worth $4 billion, focusing on growth investments in the healthcare sector. The company has offices in Boston, Amsterdam, and London. By combining private equity expertise with operational knowledge, it collaborates with the management teams of its portfolio companies to create value and drive long-term performance. Ampersand has helped to build several companies that are leaders in their respective core healthcare areas. For more information, please visit www.ampersandcapital.com or follow us on LinkedIn.
